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Hair Follicle Mesenchyme-Associated PD-L1 Regulates
T-Cell Activation Induced Apoptosis: A Potential
Mechanism of Immune Privilege
Xiaojie Wang1, Alexandra K. Marr2, Trisia Breitkopf1, Gigi Leung1, Jianqiang Hao3, Eddy Wang1,
Nicole Kwong3, Noushin Akhoundsadegh1, Lieping Chen4, Alice Mui3, Nicholas Carr3, Garth L. Warnock3,
Jerry Shapiro1 and Kevin J. McElwee1
The immune privilege (IP) of hair follicles (HFs) has been well established in previous studies. However, whether
cultured HF cells still exhibit IP properties, the individual factors involved in this process, and the detailed
mechanisms that drive and maintain IP, are largely unidentified. We found preferential expression of
IP-associated genes in cultured HF dermal papilla and dermal sheath cup cells (DSCCs) compared with non-
follicular fibroblasts (FBs) at passage 4, suggesting a potential for functional IP. Notably, programmed cell death 1
ligand 1 (PD-L1) was significantly upregulated in DSCCs and dermal papilla cells relative to FBs. IFNg secretion
from peripheral blood mononuclear cells (PBMCs) co-cultured with histoincompatible DSCCs was significantly
lower than with FB and higher percentages of early apoptotic, Annexin Vþ cells were observed in PBMC
co-cultured with DSCCs. Knockdown of PD-L1 translation by silencing interfering RNA in DSCCs enabled
increased IFNg secretion by PBMCs, whereas transfection of pCMV6-XL4/hPD-L1 in FB significantly reduced IFNg
secretion and increased apoptosis in co-cultured PBMCs. We also found that apoptosis in allogeneic T cells
induced by DSCCs was largely dependent on the mitochondrial pathway. Our study suggests IP properties are
exhibited in cultured DSCCs in part through expression of negative co-signaling molecule PD-L1.
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INTRODUCTION
Immune privilege (IP) is a dynamic state that induces and
maintains immune tolerance in critical organs for survival
under physiological circumstances, inflammatory conditions,
and foreign cell attack (Hunt, 2006; Simpson, 2006; Forrester
et al., 2008). The notable IP sites in the body include the testis,
the placenta, the brain, and the eye. The definition of IP was
first given by Medawar (1948), who made an assumption of
immunological ignorance in prolonged survival of foreign
tissue grafts placed into the anterior chamber of the eye.
However, multiple active, rather than passive, IP mechanisms
for preventing the induction and expansion of the innate and
adaptive immune responses have subsequently been disco-
vered by different groups (Suter et al., 2003; Ito et al., 2008).
These mechanisms can include downregulated expression of
major histocompatibility complex class I and II; expression of
non-classical regulatory major histocompatibility complex I
molecules such as HLA-G; physical barriers to immune sur-
veillance; deletion of auto- or allo-reactive T cells by inducing
apoptosis such as via the Fas/FasL pathway; modulation of
co-stimulatory signals; and local production of potent
secretory immunosuppressants (Paus et al., 1994; Griffith
et al., 1995; Christoph et al., 2000; McElwee et al., 2003;
Paus et al., 2003; Carosella et al., 2008). Secreted immuno-
regulatory cytokines providing IP are many and varied
including transforming growth factor-b1/b2 (TGF-b1/b2),
IL-10, calcitonin gene-related peptide, a-melanocyte-stimula-
ting hormone, macrophage migration inhibitory factor, red/IK,
and others (Guleria et al., 2005; Hori et al., 2006; Meyer et al.,
2008; Cheng et al., 2009; Kinori et al., 2012).
Although an understanding of tissue IP has only recently
emerged, survival and growth of hair follicles (HFs) trans-
planted between different individuals is indicated in historical
medical literature (Dieffenbach, 1822). The IP of HFs was first
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examined by Billingham who demonstrated the ability of
melanocytes from guinea pigs to survive and produce pigment
when the cells were transplanted into allogeneic host albino
HFs (Billingham and Silvers, 1971). In humans, tissue from
primary HF bulbs was successfully transplanted to an
immunocompetent, HLA-mismatched donor (Reynolds et al.,
1999). Available data using primary HFs have suggested
several IP mechanisms may be active (Reynolds et al., 1999;
Paus et al., 2005; Breitkopf et al., 2013). However, whether
cultured HF cells, which can be potentially used in the
treatment of human hair loss and/or allogeneic organ/tissue
transplantation, exhibit IP has largely remained unexplored
(Ito et al., 2004; Paus et al., 2005; Kang et al., 2010; Breitkopf
et al., 2013). In addition, the detailed mechanisms and factors
in HF IP have yet to be fully defined.
We therefore investigated IP in HF dermal papilla (DP),
dermal sheath (DS), and DS cup cells (DSCCs) compared with
non-follicular fibroblasts (FB). The preliminary data showed
that cultured DP and DSCC exhibited IP. DSCC elicited hypo-
responsiveness from allogeneic T cells and inhibited T-cell
activation and proliferation by inducing apoptosis of acti-
vated T cells. We found that programmed cell death 1 ligand 1
(PD-L1, also named B7-H1, or CD274) was upregulated in
DSCC versus FB. The suppression was reversible following
knockdown of PD-L1 in DSCC. In contrast, overexpression of
PD-L1 in FB promoted hypo-responsiveness and apoptosis
induction in peripheral blood mononuclear cell (PBMC).
PD-L1 might represent a unique HF expressed factor confer-
ring IP with a potential role in inflammatory hair loss,
autoimmune diseases, and graft rejection.
RESULTS
Cell culture characterization
The cell cultures were observed to be almost exclusively
mesenchymal cells (Supplementary Figure 1 online) as demon-
strated by expression of vimentin (Wu et al., 2005; Satelli and
Li, 2011). Cell cultures were negative for K14þ keratinocytes
and gp100þ melanocytes (data not shown) as well as CD31þ
endothelial cells (Supplementary Figure 1 online). DSCC and
DP cells, but not DS or FB cells, were partially versican positive
(Supplementary Figure 1 online), a marker of hair follicle
inductive ability (Soma et al., 2005). DSCC, DP, and DS, but
not FB cells, were alpha smooth muscle actin positive (Jahoda
et al., 1984). Cultured DP, DSCC, DS, and FB populations
were negative for CD4þ and CD8þ cells (data not shown).
IP-related genes are expressed in cultured HF cells
We first examined IP-related gene expression in DSCC, DP,
and DS cells cultured for four passages relative to FB by
quantitative real-time RT-PCR (qPCR; Figure 1). Class I HLA-A
and HLA-B were significantly downregulated in both DSCC
and DP compared with FB (Figure 1). In addition, CCL2 and
IL1RA were downregulated in DP and DSCC, respectively. In
contrast, TGFB1, TGFB2, and PDL1 (PD-L1) were significantly
upregulated in DSCC and DP; HLAG, INHBA (Activin-A),
MICA, and IK (red/IK) was significantly upregulated in DSCC.
Other potential IP-related genes exhibited no significant
difference (Supplementary Figure 2 online).
PD-L1 is overexpressed in DSCC
Gene profiling showed that PD-L1 was highly upregulated in
both DSCC and DP cells (Figures 1a and 2a). By western blot,
the expression of PD-L1 protein in DSCC was 2.3-fold higher
than in FB (Figure 2b), P¼ 0.030 (Figure 2b, P¼ 0.030). In
primary tissue, we observed expression of PD-L1 in the lower
DSCC, but diminished expression along the distal HF, and
almost absent expression in non-bulbar DS. An estimated 40–
60% of DP cells were also positive for PD-L1 (Figure 2c).
Given expression of PD-L1 was highest in DSCC and lowest in
FB (Figure 2b), these cell populations were selected for sub-
sequent studies. The expression of PD-L1 was downregulated
by 60–70% at 10 nM or 20 nM of silencing interfering RNA
(siRNA; Figure 2d), but not other proteins such as TGF-b1,
TGF-b2, or HLA-G (data not shown). On the other hand, the
mRNA and protein expression of PD-L1 in FB was upregulated
by transfection (Figure 2e and f).
DSCC and DP stimulate lower allogeneic immune responses
relative to FB
We next evaluated the cells’ ability to stimulate allogeneic
immune responses using IFNg as a marker of pro-inflamma-
tory cell activation (Danzer et al., 1996). The amount of IFNg
secretion from histoincompatible PBMCs co-cultured with
DSCC or DP was significantly lower than with DS or FB
cells after 5-day incubation (Figure 3a, 24.0, 28.4, 49.5, and
55.9 pg ml–1 in DSCC, DP, DS, and FB, respectively. FB vs.
DSCC, P¼ 0.004; FB vs. DP, P¼ 0.021; FB vs. DS, P¼ 0.832;
DSCC vs. DP, P¼0.672). We further identified which T-cell
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Figure 1. The expression pattern of IP-related genes in HFs. Hair follicle
DSCC, DP, DS, and non-follicular FBs were dissected and cultured. Passage 4
cells were examined by qPCR for IP-related gene expression relative to non-
follicular FB. The fold changes were generated from duplicated values of four
healthy donors of both males and females aged on average 62.0±6.6 years
and expressed as the 2 DDCT value. *Indicates Pp0.05. CCL2, chemokine
(C-C motif) ligand 2; CD55, complement decay-accelerating factor; DP,
dermal papilla; DS, dermal sheath; DSCC, DS cup cell; FB, fibroblast; HF, hair
follicle; IL1RA, IL-1 receptor antagonist; IP, immune privilege; PD-L1,
programmed cell death 1 ligand 1; qPCR, quantitative real-time RT-PCR;
TGF-b1, transforming growth factor beta 1; TGF-b2, transforming growth factor
beta 2.
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subsets produced IFNg in response to DSCC and FB cells.
The percentage of both CD4þ IFNgþ and CD8þ IFNgþ was
reduced in the presence of DSCC as compared with FB
(Figure 3, FB vs. DSCC, P¼0.004 and P¼ 0.047 in CD4þ
IFNgþ and CD8þ IFNgþ subsets, respectively), indicating that
the ability of DSCC to promote T-cell activation was signifi-
cantly lower than that of FB.
We next examined the proliferation of CD4 versus CD8
subsets stimulated by DSCC or FB. We found that the
percentage of Ki-67þ cells in both T-cell subsets was reduced
in the presence of DSCC compared with FB (Figure 4, FB vs.
DSCC, P¼ 0.047 and P¼ 0.012 in CD4þKi-67þ and CD8þ
Ki-67þ subsets, respectively), suggesting that the capacity of
T-cell proliferation was impaired in the presence of DSCC.
Furthermore, the percentage of CD4þFoxp3þ cells was
statistically significantly increased in co-culture with DSCC
as compared with FB (Supplementary Figure 3 online).
DSCC induce early apoptosis in activated T cells
We examined whether the hypo-responsiveness induced by
DSCC in co-culture might result from T-cell apoptosis.
A significantly higher percentage of apoptotic cells were
found in both CD4þ and CD8þ subsets in the presence
of DSCC (Figure 5, 9.7% vs. 15.0% CD4þAnnexin Vþ cells,
P¼0.011; 10.1% vs. 17.2% CD8þAnnexin Vþ cells,
P¼0.025). Caspases 8 and 9 are initiators for the extrinsic
and intrinsic apoptotic pathways respectively; they activate
effector caspase 3 (Holtzman et al., 2000; Chen et al., 2007).
DSCC induced a 56% increase in activated caspase 3 in
T cells compared with FB (Figure 6a, 3.7% vs. 6.8%,
P¼0.037), suggesting a key role for the caspase-dependent
pathway in T-cell apoptosis induction by DSCC. Caspase 8
was higher, but not significantly, in T cells co-cultured with
DSCC compared with FB (Figure 6b). In contrast, caspase 9
was significantly higher in T cells co-cultured with DSCC
(Figure 6c). JC-1 green, which indicates early apoptotic cells
involving the mitochondrial pathway (Green and Reed, 1998),
was also significantly higher in T cells co-cultured with DSCC
(Figure 6d), P¼ 0.001, confirming that the intrinsic pathway is
important in this effect.
The effect of PD-L1 knockdown in DSCC on allogeneic
immune responses
We investigated how expression of PD-L1 in DSCC affected
allogeneic immune responses by siRNA knockdown
(DSCC-KD). The secretion of IFNg was significantly higher in
DSCC-KD compared with DSCC co-cultured with allogeneic
PBMCs (Figure 3a, 38.4 vs. 24.0 pg ml–1, P¼0.037), indicating
that knockdown of PD-L1 expression in DSCC partially removed
T-cell hypo-responsiveness in the allogeneic immune responses.
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Figure 2. Programmed cell death 1 ligand 1 (PD-L1) is overexpressed in dermal sheath cup cells (DSCCs). The relative expression of PD-L1 mRNA (a) and protein
(b) in DSCC at passage 4 are shown in a and b, respectively. (c) Immunohistochemistry staining of hair follicle (HF) representative of three different individuals,
both males and females, aged on average 53.0±11.2 years. PD-L1 positive cells (in brown) were present in the lowest region of DSCC and 40–60% of dermal
papilla (DP) cells, but almost absent in dermal sheath (DS). Scale bar¼ 200mm (left) 100mm (right). (d) The efficiency of silencing interfering RNA (siRNA)
knockdown of PD-L1 was tested by titration of different siRNA concentrations. The fold change of PD-L1 at the mRNA and protein level was tested by quantitative
real-time RT-PCR (qPCR) (e) and western blot (f) after transfection, respectively. Scrambled RNA and empty vector was used as controls for knockdown and
overexpression experiments, respectively. We used 10 nM of siRNA in subsequent assays. Results represent three individual experiments in duplicated repeats from
six healthy male and female donors aged on average 47.5±20.0 years. *Indicates Pp0.05. FB, fibroblasts; KD, knockdown.
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The percentage of CD4þ IFNgþ cells was significantly
increased (Figure 3b and c, 13.6% vs. 18.7%, P¼ 0.047), but
not significantly changed for CD8þ IFNgþ cells (Figure 3d and
e, 25.6% vs. 33.8%, P¼0.082), in the presence of DSCC-KD
compared with DSCC. The percentage of CD8þKi-67þ cells
was significantly increased (Figure 4c and d, 2.4% vs. 4.8%,
P¼ 0.047), but not in CD4þKi-67þ (Figure 4a and b, 2.7% vs.
4.8%, P¼0.062), in the presence of DSCC-KD compared with
DSCC, indicating that reduction of PD-L1 expression in DSCC
enabled T-cell activation and proliferation.
In addition, apoptosis was also reduced for both CD4þ
and CD8þ cells when co-cultured with PD-L1-deficient
DSCC. However, a statistically significant difference
was only observed in the CD4þ subset (Figure 5, 15.0% vs.
10.8% CD4þAnnexin Vþ cells, P¼0.028; 17.2% vs. 11.9%
CD8þAnnexin Vþ cells, P¼0.072). The effects of PD-L1
on T-cell activation, proliferation, and apoptosis was
further confirmed by a PD-L1 neutralizing antibody and
results were observed to be similar (Supplementary Figure 4
online).
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Figure 3. Dermal sheath cup cells (DSCCs) significantly inhibit allogeneic T-cell activation. Non-follicular fibroblast (FB) or DSCC, dermal papilla (DP), or dermal
sheath (DS) cells (2104) were co-cultured with allogeneic peripheral blood mononuclear cells (PBMCs; 2105) for 5 or 7 days. (a) IFNg secreted from PBMC
co-cultured with DSCC or DP was significantly lower than from FB-PBMC co-culture. IFNg secreted from PBMC co-cultured with DSCC-knockdown (KD) or
FB-PD-L1 was significantly higher and lower than that of controls, respectively. (b) Percentage of IFNg production in CD4þ or CD8þ subsets after 5 days
co-culture was presented by flow cytometric analysis. Representative dot plots (b, d) and accumulated data (c, e) from CD4þ IFNgþ (b, c) or CD8þ IFNgþ
(d, e) cell populations are shown. Scrambled silencing interfering RNA (siRNA) and empty vector were used as controls for programmed cell death 1 ligand 1
(PD-L1) knockdown and overexpression studies, respectively. Data represent three independent experiments with duplicates in each test using six samples for
each setup from a total of 10 healthy male and female donors aged on average 55.5±19.0 years. *Indicates Pp0.05. ns, no significance.
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The effect of PD-L1 overexpression in FB on allogeneic immune
responses
We next investigated how transfection of PD-L1 into FB
(FB-PD-L1) affected allogeneic immune responses. The expres-
sion of PD-L1 in FB at both mRNA and protein levels was
upregulated by transfection (Figure 2e and f). IFNg secretion
from allogeneic PBMCs was significantly lower with FB-PD-L1
compared with FB co-culture (Figure 3a, 36.3 vs. 29.5 pg ml–1,
P¼0.010), indicating that overexpression of PD-L1 in FB
reduced allogeneic immune responses.
The percentage of CD4þ IFNgþ cells was significantly
decreased (Figure 3b and c, 19.7% vs. 15.8%, P¼ 0.002)
but not for CD8þ IFNgþ cells (Figure 3d and e, 36.3% vs.
30.2%, P¼0.082) in the presence of FB-PD-L1 compared
with FB. The percentage of both CD4þKi-67þ (Figure 4a
and b, 5.6% vs. 2.9%, P¼ 0.102) and CD8þKi-67þ cells
(Figure 4c and d, 7.3% vs. 4.5%, P¼0.125) was decreased,
but not significantly, in the presence of FB-PD-L1 compared
with FB, indicating that PD-L1 overexpression in FB reduced
allogeneic immune responses.
Apoptosis in both CD4þ and CD8þ PBMC subsets was also
significantly increased when co-cultured with PD-L1-over-
expressing FB (Figure 5, 9.7% vs. 15.1% CD4þAnnexin Vþ
cells, P¼0.029; 10.1% vs. 17.2% in CD8þAnnexin Vþ cells,
P¼0.030), consistent with apoptosis induced by DSCC via
PD-L1.
DISCUSSION
We confirmed that the cultured DSCC, DP, DS, and FB
cells were mesenchymal cells and not endothelial cells,
melanocytes, or keratinocytes (Supplementary file online).
Furthermore, DSCC and DP cultures expressed versican; a
marker of hair inductive ability (Soma et al., 2005). We
investigated the potential for these cell populations to
exhibit IP function. IP involves diverse immune evasion
strategies (Hunt, 2006; Simpson, 2006; Forrester et al.,
2008). Previous HF studies have primarily evaluated IP in
epithelium and undoubtedly, epithelium IP is a key
component of HF protection (Paus et al., 2005; Meyer et al.,
2008; Kinori et al., 2011). However, in this study, we found
that HF mesenchymal cells, primarily DSCC and DP, may also
exhibit IP. Although many IP-related genes were not shown to
be differentially expressed in HF mesenchyme, 12 of them
were significantly differentially expressed in cultured DSCC
and/or DP compared with FB.
Consistent with previous reports, we found downregulation
of HLA-A and HLA-B in cultured DSCC and DP (Paus et al.,
1993, 2003; Breitkopf et al., 2013). In contrast, non-classical
Ki-67 6.34 3.29 5.984.713.07 7.56
FB-PD-L1
Ki-67 10
5
104
103
102
102 103 104 105
0
105
104
103
102
0
105
104
103
102
0
105
104
103
102
0
105
104
103
102
0
105
104
103
102
0
105
104
103
102
0
105
104
103
102
0
0
102 103 104 1050 102 103 104 1050 102 103 104 1050 102 103 104 1050 102 103 104 1050 102 103 104 1050
102 103 104 1050
5.73 3.99 6.74 3.913.19 5.75
CD4
DSCC-KD
CD8
FB DSCC
0
5
10
15
20
*P =0.047
%
 C
D4
+
Ki
-6
7+
%
 C
D8
+
Ki
-6
7+
%
 C
D8
+
Ki
-6
7+
%
 C
D8
+
Ki
-6
7+
%
 C
D4
+
Ki
-6
7+
%
 C
D4
+
Ki
-6
7+
siRNA DSCC-KD
0
5
10
15
20
ns
Vector FB-PD-L1
0
5
10
15
20
ns
FB DSCC
0
5
10
15
20 *P=0.012
siRNA DSCC-KD
0
5
10
15
20
*P=0.047
Vector FB-PD-L1
0
5
10
15
20 ns
FB DSCC
Scrambled
siRNA Vector FB-PD-L1
FB DSCC Scrambled
siRNA
DSCC-KD Vector
105
104
103
102
0
105
104
103
102
0
105
104
103
102
0
105
104
103
102
0
102 103 104 1050 102 103 104 1050 102 103 104 1050 102 103 104 1050
Figure 4. Dermal sheath cup cells (DSCCs) significantly inhibit allogeneic T-cell proliferation. Non-follicular fibroblast (FB) or DSCC cells (2 104) were co-
cultured with allogeneic peripheral blood mononuclear cells (PBMCs; 2105) for 5 or 7 days. Percentage of Ki-67 expression in CD4þ (a, b) or CD8þ (c, d)
subsets after 7 days co-culture was examined by flow cytometric analysis. Representative dot plots (a, c) and accumulated data (b, d) from CD4þKi-67þ (a, b) or
CD8þKi-67þ (c, d) cell populations are shown. Scrambled siRNA and empty vector were used as controls for programmed cell death 1 ligand 1 (PD-L1)
knockdown and overexpression studies, respectively. Data represent three independent experiments with duplicates in each test using six samples for each setup
from a total of 10 healthy male and female donors aged on average 55.5±19.0 years. *Indicates Pp0.05. ns, no significance.
X Wang et al.
PD-L1 Regulates Hair Follicle Immune Privilege
740 Journal of Investigative Dermatology (2014), Volume 134
16.55 9.4010.74
An
ne
xi
n 
V 11.56 14.48 15.51
CD4
An
ne
xi
n 
V 11.28 18.37 16.08 11.59 10.11 19.03
CD8
FB DSCC
0
10
20
30 *P =0.011
%
 C
D4
+
 
An
ne
xi
n 
V+
siRNA DSCC-KD
0
10
20
30
40
*P =0.028
%
 C
D4
+
 
An
ne
xi
n 
V+
Vector FB-PD-L1
0
10
20
30 *P =0.029
%
 C
D4
+
 
An
ne
xi
n 
V+
FB DSCC
0
10
20
30 *P =0.025
%
 C
D8
+
 
An
ne
xi
n 
V+
siRNA DSCC-KD
0
10
20
30 ns
%
 C
D8
+
 A
nn
ex
in
 V
+
Vector FB-PD-L1
0
10
20
30 *P =0.030
%
 C
D8
+
 A
nn
ex
in
 V
+
FB DSCC Scrambled siRNA DSCC-KD Vector FB-PD-L1
FB DSCC Scrambled siRNA DSCC-KD Vector FB-PD-L1
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
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knockdown and overexpression studies, respectively. Data represent three independent experiments with duplicates in each test using six samples for each setup
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class I gene HLA-G was significantly upregulated. HLA-G has
properties that are known to maintain T-cell tolerance,
including maternal–fetal immune tolerance, through inhibiting
effector and NK cells, or through generating regulatory CD4þ
T cells (Lila et al., 2002; Hunt et al., 2005; Castellaneta et al.,
2011). Secretory cytokine TGFB1 and TGFB2 mRNA were
significantly upregulated in DSCC. TGF-b molecules can
regulate processes such as immune function, proliferation,
and epithelial–mesenchymal transition. For example, TGF-b1
and TGF-b2 can convert effector T cells into suppressive
T regulatory cells (Abbas et al., 2013). Activin A, also a
member of the TGF-b superfamily, was upregulated in DSCC.
This molecule can regulate cell growth and proliferation via
stimulating transcription of cell cycle inhibitors, such as
cyclin-dependent kinase inhibitor 1A p21 (Burdette et al.,
2005). These results suggest that IP mechanisms in HF are
complex; individual factors that contribute to the IP of HFs can
vary between tissue/cell types.
IFNg is predominately produced by CD4þ Th1 and CD8þ
cytotoxic T lymphocyte effector T cells in antigen-specific
responses. IFNg augments helper T-cell differentiation and
expansion, modulates macrophage effector functions, influ-
ences isotype switching and secretion of immunoglobulins
by B cells, and upregulates major histocompatibility complex
class I and II expression (Schoenborn and Wilson, 2007).
Therefore, IFNg can be used as a surrogate marker for
allogeneic T-cell activation (Danzer et al., 1996; Breitkopf
et al., 2013). We showed a 57% inhibition of IFNg secretion
from PBMCs co-cultured with allogeneic DSCC compared
with FB, demonstrating the ability of cultured DSCC to
stimulate allogeneic immune responses continued to be
compromised at passage 4; 12–14 population doublings.
Several IP strategies have been characterized in primary HF
and other tissues (Gilhar et al., 1998; Streilein, 1988; Paus
et al., 2003, 2005, 2006; Caspi, 2006; Breitkopf et al., 2013).
Here we describe our observation that PD-L1 is expressed in
DSCC and promotes hypo-responsiveness in T cells. The
mechanisms regulating PD-L1 expression in cells are not
completely known. However, PD-L1 is expressed in several
tissues and the expression level is associated with IP status
(Guleria et al., 2005; Hori et al., 2006; Cheng et al., 2009).
PD-L1 delivers an inhibitory signal through PD-1 on T cells to
induce cell anergy (Butte et al., 2007; Azuma et al., 2008;
Park et al., 2010). The PD-1/PD-L1 pathway functions as a
cellular checkpoint to suppress ongoing immune responses
and inflammation (Butte et al., 2007; Azuma et al., 2008; Park
et al., 2010). The constitutive expression of PD-L1 in the testis
is an important mechanism underlying testicular IP and long-
term survival of intra-testicular islet allografts (Cheng et al.,
2009). PD-L1-expressing corneal tissue also has IP (Hori et al.,
2006). Overexpression of PD-L1 in placenta contributes to
feto-maternal tolerance while PD-L1 deficiency reduces
allogeneic fetus survival (Guleria et al., 2005; Habicht et al.,
2007; Ritprajak et al., 2010). Although our results are
generated from in vitro studies, we suggest that PD-L1 could
also have an important role in HF IP in vivo.
The role of PD-L1 activity in autoimmunity is implicated
from several lines of evidence. PD-1 gene polymorphisms
have been correlated to autoimmune diseases such as
systemic lupus erythematosus, rheumatoid arthritis, type 1
diabetes, and multiple sclerosis (Fife and Pauken, 2011).
PD-1-deficient rodent models develop glomerulonephritis,
autoimmune cardiomyopathy, and severe collagen-induced
arthritis (Okazaki and Honjo, 2006; Raptopoulou et al., 2010).
PD-L1-deficient mice develop experimental autoimmune
encephalomyelitis (Carter et al., 2007). In non-obese
diabetic mice, PD-L1 expression in pancreatic islets retards
lymphocyte invasion while non-obese diabetic mice deficient
for PD-1 exhibit rapid islet infiltration by lymphocytes
and diabetes onset (Okazaki and Honjo, 2006). Injection of
anti-PD-1 or anti-PD-L1 accelerates spontaneous diabetes
in non-obese diabetic mice (Ansari et al., 2003). Similarly,
neutralizing antibody exacerbates experimental autoimmune
encephalomyelitis (Salama et al., 2003). Stimulation of PD-1
using PD-L1 fusion proteins significantly reduces autoimmune
activity in induced rat experimental autoimmune glomerulo-
nephritis (Reynolds et al., 2012). Further, PD-L1 expression
was statistically significantly lower in alopecia areata affected
mice compared with controls (Duncan et al., 2013).
We found that DSCC cells have much higher expression
levels of PD-L1 than non-follicular FB. Both CD4þ and CD8þ
cell functions were impaired in the presence DSCC. Reduced
IFNg secretion from PBMC co-cultured with PD-L1 over-
expressed in FB indicates PD-L1 expression can confer IP. In
contrast, lower expression of PD-L1 in DSCC resulted in
higher levels of IFNg secretion from co-cultured PBMCs,
indicating PD-L1 is an important factor for maintaining IP in
DSCC. Changes in IFNg secretion in both CD4þ and CD8þ
cell subsets were observed, but the data suggest PD-L1 has a
relatively greater influence on CD4þ cells.
Induction of T-cell apoptosis has been suggested as one of
the mechanisms for induction and maintenance of IP in
placenta, testis, and cornea (Guleria et al., 2005; Hori et al.,
2006; Cheng et al., 2009). We found that DSCC induced a
higher percentage of early apoptosis in both CD4þ and
CD8þ T cells compared with FB. Decreased apoptosis was
found when PD-L1 was knocked down in DSCC; in contrast, a
significant increase in apoptosis occurred when PD-L1 was
overexpressed in FB. The data confirm that PD-L1-expressing
DSCC maintain the ability to suppress immune responses in
part through induction of early apoptosis.
Apoptosis can be initiated by two main pathways: the
extrinsic death receptor pathway and the intrinsic mito-
chondrial pathway. Caspase 3 is considered to be the most
important effector caspase and is activated by initiator
caspases 8 or 9 depending which pathway dominates; the
extrinsic and intrinsic pathways activate caspases 8 and 9,
respectively (Holtzman et al., 2000; Askenasy et al., 2005;
Orbach et al., 2007). In this study, DSCC-induced apoptosis in
T cells associated with increased caspase 3 activation.
Furthermore, DSCC increased caspase 9 expression and JC-1
mitochondrial membrane potential rather than caspase 8,
suggesting that apoptosis induced by DSCC is mainly
triggered via the intrinsic pathway.
In summary, the data suggest a mechanism for HF IP. PD-L1
may represent a predictive marker for induction and
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maintaining IP status in tissues per cells. We also show that
cultured DSCC exhibit IP, consistent with potential for use in
treatment of inflammatory hair loss, autoimmune diseases, and
allogeneic transplantation.
MATERIALS AND METHODS
Microdissection of human HF cells and isolation of PBMCs
Tissues were obtained from men and women aged from 20 to 60
undergoing cosmetic surgery with University Clinical Research Ethics
Board approval and maintaining Declaration of Helsinki Principles.
Consent was not required as tissues obtained from surgical proce-
dures are considered discarded under Canadian law. PBMCs, from 14
healthy men and women aged on average 57.4±16.4 years who
gave informed consent, were isolated by Ficoll-paque (GE Life
Science, Baie d’Urfe, Quebec, Canada). PBMCs were cultured in
1640 RPMI complete medium containing 10% heat-inactivated FBS
(Invitrogen, Burlington, Ontario, Canada). DS cup, DP, non-bulbar
DS tissues, and non-follicular dermal tissue containing FB were
dissected. Briefly, epidermis, dermis, and fat were removed as well
as the HF infundibulum. The HFs were cut to separate the lower bulb
region, the bulb was then inverted and cut into the lowest portion of
‘‘cup’’ and DP. The DS was removed from the non-bulbar root
sheaths and hair shaft. The individual tissues were cultured in
AmnioMax C-100 (Invitrogen). The passage number is defined as
each de-attachment using trypsin (Invitrogen) and re-attachment to
the culture flasks. Passage 4 cells were used in all assays. In co-
culture experiments, half of RPMI 1640 complete medium and half of
AmnioMax were used in a u-bottomed plate.
ELISA
IFNg secretion was determined by a standard sandwich ELISA using a
kit (eBioscience, San Diego, CA) according to the manufacturer’s
instructions and detected at 450 nm with a correction of 540 nm
(n¼ 3 per group; in triplicates per group). Standard curves were
created by optical density readings and sample values were calcu-
lated by this standard curve.
RNA isolation, complementary DNA synthesis, and quantitative
RT-PCR
Total RNA from cultured DSCC, DP, DS, and FB (n¼ 4 per group)
were extracted by a standard protocol, as previously described, using
the RNeasy Mini Kit (Qiagen, Mississauga, Canada) with its on-
column RNase-free DNase I procedure. Complementary DNA was
then synthesized by Superscript III Reverse Transcriptase (Invitrogen)
in 20ml reaction including 0.5mg RNA and 150 ng random primer in
addition to other kit components according to the manufacturer’s
protocol. RNaseH was utilized to remove complementary RNA.
QPCR was performed in duplicate using DyNAmo HS SYBR Green
qPCR kit (New England Biolabs, Mississauga, Canada) in a 20ml
volume containing 1 ngml–1 of complementary DNA and 0.4mM of
each primer (Breitkopf et al., 2013). Relative expression level was
expressed as 2 (CT18s-CTgene) (where CT is the cycling threshold) with
18S RNA as the endogenous control for normalization.
Immunohistochemistry
Scalp tissues (n¼ 3) were formalin fixed, paraffin embedded, and
sections cut at 5mm. Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide followed by incubation with rabbit
anti-human PD-L1 (Abcam, Toronto, Canada), horseradish peroxi-
dase-conjugated secondary anti-rabbit antibody (BD, Mississauga,
Canada), 3,30-diaminobenzidine substrate, and counterstained with
hematoxylin (Sigma, Oakville, Canada).
Western blot
In all, 25mg of each cell lysate from cultured HF cells or FBs (n¼ 3
samples per group) were loaded onto a 12% separating Bis-Tris gel.
The proteins were transferred to a nitrocellulose membrane (Bio-Rad,
Mississauga, Canada). The membrane was blocked in phosphate-
buffered saline containing 5% skim milk for 1 hour followed by incu-
bation with the primary antibody rabbit anti-mouse PD-L1 (Abcam) or
mouse anti-actin at a concentration of 2.5mg ml–1. Secondary anti-
bodies for PD-L1 and actin were goat anti-rabbit and goat anti-mouse
(BD) conjugated with horseradish peroxidase, respectively. The blot
was developed with Enhanced Chemiluminescence Plus Developer
(Pierce, Nepean, Canada). The protein expression level was calcu-
lated using ImageJ software (Schneider et al., 2012).
Flow cytometric analysis
For each sample, 106 cells were stained with anti-CD4, anti-CD8,
Ki-67, anti-CD3, Annexin V, 7AAD, or isotype control rat IgG (all
eBioscience). Intracellular staining of IFNg was performed after
4 hours stimulation with phorbol 12-myristate 13-acetate and iono-
mycin (Sigma). Activated caspase 3 (BD #557091, polyclonal rabbit
anti-active caspase 3), active caspase 8 (eBioscience #88-7005,
fluorescein-conjugated IETD-FMK), caspase 9 (eBioscience #88-
7006, fluorescein-conjugated LEHD-FMK), and JC-1 (eBioscience
#65-0851; Green and Reed, 1998) was stained according to the
manufacturer’s instructions. A total of 20,000 live gated events were
acquired on FACScan (BD), and FlowJo software (Tree Star, Ashland,
OR) was used to analyze relevant populations.
Knockdown and overexpression of PD-L1
The expression of PD-L1 was knocked down by RNAiMax transfec-
tion (Invitrogen) or electroporation (Bio-Rad) of duplex siRNA-27
(rGrCrArArUrArUrGrArCrArArUrUrGrArArUrGrCrArArATT, rGrCrCr
GrArCrUrArCrArArGrCrGrArArUrUrArCrUrGrUGA), and overexpres-
sion of PD-L1 was achieved by lipofectamine LTX & plus transfection
(Invitrogen) of pCMV6-XL4/hPD-L1 (Dong et al., 2002). The expres-
sion of mRNA and protein were examined by qPCR and western blot
at 48 and 72 hours, respectively (n¼ 3 per group; in duplicates per
sample). Universal scrambled negative control siRNA duplex
(OriGene Technologies, Rockville, MD) was used for siRNA control
along with the empty vector without PD-L1 sequence.
Statistics
qPCR, ELISA, and flow cytometry data were analyzed by two-tailed
Student’s t-tests. For all figures, we state no significance if P-value is
40.05. Differences are considered significant if Pp0.05.
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